Table 2.
Reference | Location | Diagnosis | Sample | Units | Cases | Controls | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
n | Subgroups | mean | SD | n | Subgroups | Mean | SD | |||||
Karege et al. (2005) | Switzerland | MDD, BD | Hippocampus | ng/g | 22 | Drug‐free MDD | 17.7 | 2.9 | 8 | Drug‐free | 24.5 | 3.6 |
Drug‐free others | 16.8 | 3.1 | ||||||||||
Drug‐treated MDD | 23.3 | 2.2 | ||||||||||
Banerjee et al. (2013) | India | MDD, BD, AD, SCZ, FD, MD | Hippocampus | pg/ml | 21 | 19.5 | — | 19 | 44 | — | ||
Dwivedi et al. (2003) | EE.UU. | MDD, AD, BD, SCZ | Hippocampus | Optical density | 27 | Suicide/MDD | 1.04 | 0.20 | 21 | 1.71 | 0.44 | |
Suicide/OPD | 1.03 | 0.22 | ||||||||||
Hayley et al. (2015) | Hungary | MDD | Hippocampus | Optical density | 9 | Females‐Hippocampus | 0.65 | — | 10 | Females‐Hippocampus | 0.55 | — |
10 | Males‐Hippocampus | 0.40 | 9 | Males‐Hippocampus | 0.75 | |||||||
Mansur et al. (20160 | Brazil | BD | Plasma | pg/ml | 57 | — | 26 | — | ||||
Grah et al. (2014) | Croatia | AD, MDD | Serum | ng/ml | 96 | (26) RDD | 11.8 | — | 106 | (60) C | 13.40 | — |
(33) PD | 10.7 | (25) RDD | 12.80 | |||||||||
(37) AD | 12.6 | (26) PD | 15.70 | |||||||||
(25) AD | 15.40 | |||||||||||
Martinez et al. (2012) | EE.UU. | MDD | CFS | pg/ml | 18 | — | 25 | — | ||||
Hayley et al. (2015) | Hungary | MDD | PFC, hippocampus | Optical density | 9 | Females | — | 10 | Females | — | ||
PFC | 0.75 | PFC | 1.40 | |||||||||
Hippocampus | 0.65 | Hippocampus | 0.55 | |||||||||
10 | Males | 9 | Males | |||||||||
PFC | 0.50 | PFC | 0.40 | |||||||||
Hippocampus | 0.40 | Hippocampus | 0.75 |
MDD, major depression disorder; BD, bipolar disorder; AD, adjustment disorder; SZC, schizophrenia; FD, familiar disharmony; MD, marital disharmony; OPD, other psychiatric disorder; RDD, recurrent depressive disorder; MAD, mood and anxiety disorder; PD, psychiatric disorder; PPAD, postpartum affective disorder; PFC, prefrontal cortex; C, control.